Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B Faries,John F Thompson,Alistair J Cochran,Robert H Andtbacka,Nicola Mozzillo,Jonathan S Zager,Tiina Jahkola,Tawnya L Bowles,Alessandro Testori,Peter D Beitsch,Harald J Hoekstra,Marc Moncrieff,Christian Ingvar,Michel W J M Wouters,Michael S Sabel,Edward A Levine,Doreen Agnese,Michael Henderson,Reinhard Dummer,Carlo R Rossi,Rogerio I Neves,Steven D Trocha,Frances Wright,David R Byrd,Maurice Matter,Eddy Hsueh,Alastair MacKenzie-Ross,Douglas B Johnson,Patrick Terheyden,Adam C Berger,Tara L Huston,Jeffrey D Wayne,B Mark Smithers,Heather B Neuman,Schlomo Schneebaum,Jeffrey E Gershenwald,Charlotte E Ariyan,Darius C Desai,Lisa Jacobs,Kelly M McMasters,Anja Gesierich,Peter Hersey,Steven D Bines,John M Kane,Richard J Barth,Gregory McKinnon,Jeffrey M Farma,Erwin Schultz,Sergi Vidal-Sicart,Richard A Hoefer,James M Lewis,Randall Scheri,Mark C Kelley,Omgo E Nieweg,R Dirk Noyes,Dave S B Hoon,He-Jing Wang,David A Elashoff,Robert M Elashoff
DOI: https://doi.org/10.1056/NEJMoa1613210
2017-06-08
Abstract:Background: Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for patients with sentinel-node metastases is not clear. Methods: In an international trial, we randomly assigned patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observation with ultrasonography (observation group). The primary end point was melanoma-specific survival. Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node metastasis. Results: Immediate completion lymph-node dissection was not associated with increased melanoma-specific survival among 1934 patients with data that could be evaluated in an intention-to-treat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, the mean (±SE) 3-year rate of melanoma-specific survival was similar in the dissection group and the observation group (86±1.3% and 86±1.2%, respectively; P=0.42 by the log-rank test) at a median follow-up of 43 months. The rate of disease-free survival was slightly higher in the dissection group than in the observation group (68±1.7% and 63±1.7%, respectively; P=0.05 by the log-rank test) at 3 years, based on an increased rate of disease control in the regional nodes at 3 years (92±1.0% vs. 77±1.5%; P<0.001 by the log-rank test); these results must be interpreted with caution. Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005). Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those in the observation group. Conclusions: Immediate completion lymph-node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma-specific survival among patients with melanoma and sentinel-node metastases. (Funded by the National Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895 .).